Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

Attention to age: similar dosing regimens lead to different vancomycin levels among older and younger patients.

Yahav D, Abbas M, Nassar L, Ghrayeb A, Shepshelovich D, Kurnik D, Leibovici L, Paul M.

Age Ageing. 2019 Nov 11. pii: afz135. doi: 10.1093/ageing/afz135. [Epub ahead of print]

PMID:
31711101
2.

Guidance on reporting multivariable regression models in CMI.

Leibovici L, Scudeller L, Kalil A, Huttner A, Leeflang MMG, Bielicki J, Allerberger F, Paul M, Rodríguez-Baño J.

Clin Microbiol Infect. 2019 Nov 7. pii: S1198-743X(19)30592-0. doi: 10.1016/j.cmi.2019.10.037. [Epub ahead of print] No abstract available.

PMID:
31707134
3.

Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults-Authors' reply.

Pertzov B, Eliakim-Raz N, Atamna H, Trestioreanu AZ, Yahav D, Leibovici L.

Clin Microbiol Infect. 2019 Aug 29. pii: S1198-743X(19)30475-6. doi: 10.1016/j.cmi.2019.08.015. [Epub ahead of print] No abstract available.

PMID:
31473328
4.

Submissions to CMI: a new CMI guide for authors.

Leibovici L, Friedman J.

Clin Microbiol Infect. 2019 Nov;25(11):1299. doi: 10.1016/j.cmi.2019.07.029. Epub 2019 Aug 8. No abstract available.

PMID:
31401174
5.

Meta-analysis of Polymyxin Use in Patients.

Paul M, Zusman O, Leibovici L.

Adv Exp Med Biol. 2019;1145:143-153. doi: 10.1007/978-3-030-16373-0_11.

PMID:
31364077
6.

Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection - a multi-site retrospective study.

Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Abdel Fattah M, Haquin J, Macgowan A, Grier S, Gibbs J, Chazan B, Yanovskay A, Ben Ami R, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Mauer S, Bano JR, Morales I, Oliver A, Ruiz de Gopegui E, Cano A, Machuca I, Gozalo-Marguello M, Martinez LM, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstein Y, Leibovici L, Yahav D.

Clin Infect Dis. 2019 Jul 17. pii: ciz668. doi: 10.1093/cid/ciz668. [Epub ahead of print]

PMID:
31323088
7.

CMI: how did we do in 2018?

Friedman J, Leibovici L.

Clin Microbiol Infect. 2019 Sep;25(9):1057-1059. doi: 10.1016/j.cmi.2019.06.001. Epub 2019 Jun 11. No abstract available.

PMID:
31266677
8.

An open call to join the CMI editorial team.

Leibovici L.

Clin Microbiol Infect. 2019 Aug;25(8):921. doi: 10.1016/j.cmi.2019.05.001. Epub 2019 May 14. No abstract available.

PMID:
31100422
9.

Reply to De Greef et al. on "Should we treat bacteremic prostatitis for 7 days?"

Yahav D, Mussini C, Leibovici L, Paul M.

Clin Infect Dis. 2019 May 11. pii: ciz393. doi: 10.1093/cid/ciz393. [Epub ahead of print] No abstract available.

PMID:
31076747
10.

The association of vancomycin trough levels with outcomes among patients with methicillin-resistant Staphylococcus aureus (MRSA) infections: Retrospective cohort study.

Yahav D, Abbas M, Nassar L, Ghrayeb A, Kurnik D, Shepshelovich D, Leibovici L, Paul M.

PLoS One. 2019 Apr 4;14(4):e0214309. doi: 10.1371/journal.pone.0214309. eCollection 2019.

11.

Should we use ethnicity as a risk factor for infection?

Leibovici L.

Clin Microbiol Infect. 2019 May;25(5):533. doi: 10.1016/j.cmi.2019.03.006. Epub 2019 Mar 14. No abstract available.

PMID:
30880240
12.

Reply to MacFadden and Hanage and to Pallett et al.

Paul M, Yahav D, Mussini C, Leibovici L.

Clin Infect Dis. 2019 Sep 13;69(7):1263-1264. doi: 10.1093/cid/ciz105. No abstract available.

PMID:
30726885
13.

Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer.

Stern A, Carrara E, Bitterman R, Yahav D, Leibovici L, Paul M.

Cochrane Database Syst Rev. 2019 Jan 3;1:CD012184. doi: 10.1002/14651858.CD012184.pub2.

PMID:
30605229
14.

Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study.

Gomila A, Carratalà J, Eliakim-Raz N, Shaw E, Wiegand I, Vallejo-Torres L, Gorostiza A, Vigo JM, Morris S, Stoddart M, Grier S, Vank C, Cuperus N, Van den Heuvel L, Vuong C, MacGowan A, Leibovici L, Addy I, Pujol M; COMBACTE MAGNET WP5 RESCUING Study Group and Study Sites.

Infect Drug Resist. 2018 Dec 18;11:2571-2581. doi: 10.2147/IDR.S185753. eCollection 2018.

15.

Clustered observations.

Leibovici L.

Clin Microbiol Infect. 2019 Jan;25(1):1. doi: 10.1016/j.cmi.2018.11.022. No abstract available.

PMID:
30579440
16.

Reply to: Replacing Urine Catheters for Urinary Tract Infections: A Closer Look.

Babich T, Leibovici L, Avni T.

J Am Geriatr Soc. 2019 Mar;67(3):621-622. doi: 10.1111/jgs.15723. Epub 2018 Dec 21. No abstract available.

PMID:
30578549
17.

Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial.

Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, Neuberger A, Ghanem-Zoubi N, Santoro A, Eliakim-Raz N, Pertzov B, Steinmetz T, Stern A, Dickstein Y, Maroun E, Zayyad H, Bishara J, Alon D, Edel Y, Goldberg E, Venturelli C, Mussini C, Leibovici L, Paul M; Bacteremia Duration Study Group.

Clin Infect Dis. 2019 Sep 13;69(7):1091-1098. doi: 10.1093/cid/ciy1054.

PMID:
30535100
18.

What are our aims at CMI?

Leibovici L; CMI Editors.

Clin Microbiol Infect. 2018 Dec;24(12):1225-1226. doi: 10.1016/j.cmi.2018.11.001. No abstract available.

PMID:
30473250
19.

Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - A systematic review and meta-analysis.

Pertzov B, Eliakim-Raz N, Atamna H, Trestioreanu AZ, Yahav D, Leibovici L.

Clin Microbiol Infect. 2019 Mar;25(3):280-289. doi: 10.1016/j.cmi.2018.11.003. Epub 2018 Nov 23.

PMID:
30472427
20.

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.

Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group .

Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988.

PMID:
30462182
21.

Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.

Doernberg SB, Tran TTT, Tong SYC, Paul M, Yahav D, Davis JS, Leibovici L, Boucher HW, Corey GR, Cosgrove SE, Chambers HF, Fowler VG, Evans SR, Holland TL; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2019 May 2;68(10):1691-1698. doi: 10.1093/cid/ciy766.

22.

Antibiotic Treatment for Uncomplicated Urinary Tract Infections-Reply.

Huttner A, Leibovici L, Harbarth S.

JAMA. 2018 Sep 25;320(12):1284-1285. doi: 10.1001/jama.2018.10018. No abstract available.

PMID:
30264110
23.

Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections.

Gomila A, Shaw E, Carratalà J, Leibovici L, Tebé C, Wiegand I, Vallejo-Torres L, Vigo JM, Morris S, Stoddart M, Grier S, Vank C, Cuperus N, Van den Heuvel L, Eliakim-Raz N, Vuong C, MacGowan A, Addy I, Pujol M; COMBACTE-MAGNET WP5- RESCUING Study.

Antimicrob Resist Infect Control. 2018 Sep 14;7:111. doi: 10.1186/s13756-018-0401-6. eCollection 2018.

24.

Randomized controlled trials in CMI.

Leibovici L, Paul M.

Clin Microbiol Infect. 2018 Oct;24(10):1031-1032. doi: 10.1016/j.cmi.2018.08.008. Epub 2018 Aug 15. No abstract available.

25.

Replacement of Urinary Catheter for Urinary Tract Infections: A Prospective Observational Study.

Babich T, Zusman O, Elbaz M, Ben-Zvi H, Paul M, Leibovici L, Avni T.

J Am Geriatr Soc. 2018 Sep;66(9):1779-1784. doi: 10.1111/jgs.15517. Epub 2018 Aug 10.

PMID:
30094820
26.

Corticosteroids Reduce Mortality in Patients With Severe Community-Acquired Pneumonia.

Stern A, Leibovici L, Paul M.

Clin Infect Dis. 2018 Oct 15;67(9):1467. doi: 10.1093/cid/ciy336. No abstract available.

PMID:
29897416
27.

Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group).

Eliakim-Raz N, Babitch T, Shaw E, Addy I, Wiegand I, Vank C, Torre-Vallejo L, Joan-Miquel V, Steve M, Grier S, Stoddart M, Nienke C, Leo VDH, Vuong C, MacGowan A, Carratalà J, Leibovici L, Pujol M; RESCUING Study Group.

Clin Infect Dis. 2019 Jan 1;68(1):29-36. doi: 10.1093/cid/ciy418.

PMID:
29788118
28.

The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.

Zak-Doron Y, Dishon Benattar Y, Pfeffer I, Daikos GL, Skiada A, Antoniadou A, Durante-Mangoni E, Andini R, Cavezza G, Leibovici L, Yahav D, Eliakim-Raz N, Carmeli Y, Nutman A, Paul M; AIDA Study Group.

Clin Infect Dis. 2018 Nov 28;67(12):1815-1823. doi: 10.1093/cid/ciy371.

PMID:
29718143
29.

Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.

Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S.

JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627.

30.

Colistin versus colistin plus meropenem for severe infections Authors' reply.

Paul M, Carmeli Y, Daikos GL, Durante-Mangoni E, Theuretzbacher U, Mouton JW, Leibovici L.

Lancet Infect Dis. 2018 May;18(5):495-496. doi: 10.1016/S1473-3099(18)30223-8. No abstract available.

PMID:
29695358
31.

CMI has a new website.

Leibovici L.

Clin Microbiol Infect. 2018 Jun;24(6):565. doi: 10.1016/j.cmi.2018.04.010. Epub 2018 Apr 22. No abstract available.

32.

Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study.

Vallejo-Torres L, Pujol M, Shaw E, Wiegand I, Vigo JM, Stoddart M, Grier S, Gibbs J, Vank C, Cuperus N, van den Heuvel L, Eliakim-Raz N, Carratala J, Vuong C, MacGowan A, Babich T, Leibovici L, Addy I, Morris S; RESCUING Study Group and Study Sites.

BMJ Open. 2018 Apr 12;8(4):e020251. doi: 10.1136/bmjopen-2017-020251.

33.

The temptation of large numbers.

Leibovici L, Turjeman A, Paul M.

Clin Microbiol Infect. 2018 Sep;24(9):931-932. doi: 10.1016/j.cmi.2018.04.002. Epub 2018 Apr 10. No abstract available.

34.

Implementation of a competency-based medical education approach in public health and epidemiology training of medical students.

Dankner R, Gabbay U, Leibovici L, Sadeh M, Sadetzki S.

Isr J Health Policy Res. 2018 Feb 20;7(1):13. doi: 10.1186/s13584-017-0194-8.

35.

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L.

Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.

PMID:
29456043
36.

Influenza vaccines in immunosuppressed adults with cancer.

Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M.

Cochrane Database Syst Rev. 2018 Feb 1;2:CD008983. doi: 10.1002/14651858.CD008983.pub3. Review.

37.

Secular trends in the appropriateness of empirical antibiotic treatment in patients with bacteremia: a comparison between three prospective cohorts.

Daitch V, Akayzen Y, Abu-Ghanem Y, Eliakim-Raz N, Paul M, Leibovici L, Yahav D.

Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):455-462. doi: 10.1007/s10096-018-3190-1. Epub 2018 Jan 20.

PMID:
29353378
38.

Emerging infections in CMI.

Leibovici L.

Clin Microbiol Infect. 2018 Apr;24(4):327. doi: 10.1016/j.cmi.2017.12.014. Epub 2018 Jan 5. No abstract available.

39.

Determinants of inappropriate empirical antibiotic treatment: systematic review and meta-analysis.

Carrara E, Pfeffer I, Zusman O, Leibovici L, Paul M.

Int J Antimicrob Agents. 2018 Apr;51(4):548-553. doi: 10.1016/j.ijantimicag.2017.12.013. Epub 2017 Dec 23. Review.

PMID:
29277528
40.

Drug Development for Multidrug-Resistant Bacteria: Why Compromise?

Paul M, Leibovici L.

J Infect Dis. 2018 Jan 17;217(3):508-509. doi: 10.1093/infdis/jix536. No abstract available.

PMID:
29240890
41.

Corticosteroids for pneumonia.

Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M.

Cochrane Database Syst Rev. 2017 Dec 13;12:CD007720. doi: 10.1002/14651858.CD007720.pub3. Review.

42.

Colistin exposure as a risk factor for infections caused by inherently colistin resistant Enterobacteriaceae-a case-control study.

Drozdinsky G, Ben-Zvi H, Kushnir S, Leibovici L, Yahav D.

Clin Microbiol Infect. 2018 Aug;24(8):896-899. doi: 10.1016/j.cmi.2017.11.022. Epub 2017 Dec 5.

43.

CMI workshop in Shanghai, China.

Leibovici L, Xu JF.

Clin Microbiol Infect. 2018 Mar;24(3):213. doi: 10.1016/j.cmi.2017.11.014. Epub 2017 Nov 22. No abstract available.

44.

A decision support model to predict the presence of an acute infiltrate on chest radiograph.

Zusman O, Farbman L, Elbaz M, Daitch V, Cohen M, Eliakim-Raz N, Babich T, Paul M, Leibovici L, Yahav D.

Eur J Clin Microbiol Infect Dis. 2018 Feb;37(2):227-232. doi: 10.1007/s10096-017-3119-0. Epub 2017 Oct 24.

PMID:
29063987
45.

Empirical Antibiotic Treatment Does Not Improve Outcomes in Catheter-Associated Urinary Tract Infection: Prospective Cohort Study.

Babich T, Zusman O, Elbaz M, Ben-Zvi H, Paul M, Leibovici L, Avni T.

Clin Infect Dis. 2017 Nov 13;65(11):1799-1805. doi: 10.1093/cid/cix680.

PMID:
29020203
46.

Are we making an impact?

Leibovici L.

Clin Microbiol Infect. 2017 Nov;23(11):783-784. doi: 10.1016/j.cmi.2017.07.027. Epub 2017 Aug 3. No abstract available.

47.

Interventions for the prevention of recurrent erysipelas and cellulitis.

Dalal A, Eskin-Schwartz M, Mimouni D, Ray S, Days W, Hodak E, Leibovici L, Paul M.

Cochrane Database Syst Rev. 2017 Jun 20;6:CD009758. doi: 10.1002/14651858.CD009758.pub2. Review.

48.

A new series of reviews in CMI: 'How to … '.

Leibovici L.

Clin Microbiol Infect. 2017 Dec;23(12):893. doi: 10.1016/j.cmi.2017.06.001. Epub 2017 Jun 9. No abstract available.

49.

Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.

Beyar-Katz O, Dickstein Y, Borok S, Vidal L, Leibovici L, Paul M.

Cochrane Database Syst Rev. 2017 Jun 3;6:CD003914. doi: 10.1002/14651858.CD003914.pub4. Review.

50.

What can we learn from our peer reviewers.

Leibovici L.

Clin Microbiol Infect. 2017 Oct;23(10):687. doi: 10.1016/j.cmi.2017.05.011. Epub 2017 May 12. No abstract available.

Supplemental Content

Loading ...
Support Center